Market Access: Pharma

Mock Negotiations and Payer Consultations

Full-service solutions tailored to your needs

Alira Health provides a range of mock negotiation and payer consultation solutions to deliver commercial success, including:
  • Generation of integrated payer evidence and analyses plans to support market access and P&R
  • Preparation and facilitation of international payer-expert advisory boards to optimize development programs and gather insights on product value and evidence requirements
  • Design and facilitation of product value workshops with cross-functional and international teams
  • Payer/Health Technology Assessment (HTA) landscape assessments

Why choose Alira Health?

As your partner, we’ll work closely with you to uncover opportunities across the pharma industry, accelerate innovation, and deliver tomorrow’s standard of care. You’ll benefit from our:

  • Access to a diverse

    integrated team with deep industry expertise

  • Close collaboration

    with our regulatory and clinical

  • Specific, local insights

    as part of your larger, global strategy—a benefit of having market access teams in both the EU and U.S.

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Jean-François Ricci
Jean-François Ricci
Executive Vice President, Global Market Access
Our strong client partnerships allow us to deliver in-depth, customized strategies and access solutions—all designed to maximize product value across its full lifecycle.

Related News

Publications September 19, 2023
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
CDMO Pharma
News August 31, 2023
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Life Sciences MedTech Pharma
Publications August 1, 2023
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
EU Pharma Regulatory
Publications July 25, 2023
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Market Access Pharma
Blog July 24, 2023
What EU Companies Need to Know about the U.S. Inflation Reduction Act
We spoke with our inhouse experts to learn about the significance of the US Inflation Reduction Act for EU pharma and biotech companies.
Biotech Drug Development Pharma
Publications July 11, 2023
Mid-size Pharma Accelerates Early Clinical Trial Engagement of Patients with A Rare Neurological Disease
A mid-size pharma company sought an experienced advisor who could help them engage patients for an open-label extension clinical study in a rare neurological disease.
Clinical Trials Patient Engagement Pharma Rare Disease
Publications July 10, 2023
The EU Pharmaceutical Package: Regulatory Protection Changes
Our regulatory experts present a more detailed analysis of the proposed changes introduced to Regulatory Data Protection (RDP).
EU Pharma Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.